Tag : IL-6R

CONFERENCE UPDATE

Updated long-term efficacy of satralizumab in relapse prevention for AQP4-IgG+ NMOSD patients in the SAkuraMoon study
Satralizumab is a monoclonal recycling antibody that targets the interleukin-6 receptor (IL-6R). Two randomized, placebo-controlled, phase 3 clinical trials, SakuraSky and SAkuraStar, had demonstrated the significant reductive effect and favorable safety and tolerability profile of 120mg satralizumab subcutaneous (SC) administration in the risk of relapse in patients with aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD).